BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/15/2019 7:18:19 AM | Browse: 979 | Download: 1467
 |
Received |
|
2019-02-17 14:46 |
|
Peer-Review Started |
|
2019-02-18 03:23 |
|
To Make the First Decision |
|
2019-02-20 00:31 |
|
Return for Revision |
|
2019-02-20 01:30 |
|
Revised |
|
2019-03-10 13:02 |
|
Second Decision |
|
2019-03-11 10:43 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-03-11 18:04 |
|
Articles in Press |
|
2019-03-11 18:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-03-15 00:29 |
|
Typeset the Manuscript |
|
2019-03-15 00:44 |
|
Publish the Manuscript Online |
|
2019-03-15 07:18 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Review |
| Article Title |
Crosstalk between gut microbiota and antidiabetic drug action
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yevheniia Kyriachenko, Tetyana Falalyeyeva, Oleksandr Korotkyi, Nataliia Molochek and Nazarii Kobyliak |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nazarii Kobyliak, PhD, Assistant Professor, Department of Endocrinology, Bogomolets National Medical University, Bogomolets National Medical University, T. Shevchenko boulevard, 13, Kyiv, 01601, Ukraine. nazariikobyliak@gmail.com., Kyiv 01601, Ukraine. nazariikobyliak@gmail.com |
| Key Words |
Type 2 diabetes; Gut microbiota; Metformin; α-glucosidase inhibitors; Glucagon-like peptide-1 agonists; Peroxisome proliferator-activated receptors γ agonists; Dipeptidyl peptidase-4 inhibitors; Sodium/glucose cotransporter inhibitors |
| Core Tip |
Gut microbiota was found to have an influence on host metabolism, food consumption, satiety, glucose homoeostasis and weight gain. Altered intestinal microbiota composition has been noticed in cardiovascular diseases, colon cancer, rheumatoid arthritis, type 2 diabetes and obesity. Therefore, the main effect of anti-diabetic drugs is on the microbiome composition, basically increasing the short-chain fatty acids-producing bacteria, responsible for losing weight and suppressing the inflammation. |
| Publish Date |
2019-03-15 07:18 |
| Citation |
Kyriachenko Y, Falalyeyeva T, Korotkyi O, Molochek N, Kobyliak N. Crosstalk between gut microbiota and anti-diabetic drug action. World J Diabetes 2019; 10(3): 154-168 |
| URL |
https://www.wjgnet.com/1948-9358/full/v10/i3/154.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v10.i3.154 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
